Kyowa Hakko Kirin Co., Limited

Kyowa Hakko Kogyo Co., Ltd.

Fujifilm Corporation

Yushi Kitamura

Yutaka Kanda

Yoshinori Yamashita

Takayuki Nakashima

Takashi Sawada

Chikara Murakata

Shiro Akinaga

Yoshisuke Nakasato

Yukimasa Shiotsu

Fumihiko Kanai

Noriaki Uesaka

Nobuyoshi Amishiro

Ryuichiro Nakai

Shinji Nara

Shiro Soga

Masamori Sugawara

Takashi Kuwabara

Kazuhiko Kato

Tadakazu Akiyama

Hiroshi Nakagawa

Jiro Kajita

Atsuko Mizutani

Rieko Nakatsu

Naoto Osakada

Satoshi Kaneko

Keishi Katayama

Mariko Osakada

Eiichi Fuse

Kenichi Yasoshima

Yoji Ino

A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein Rrepresents a hydrogen atom and the like, Rrepresents a hydrogen atom, &#x2014;C(&#x2550;W)R(wherein W represents an oxygen atom or a sulfur atom, and Rrepresents substituted or unsubstituted lower alkyl and the like) and the like, Rrepresents &#x2014;C(&#x2550;Z)R(wherein Z represents an oxygen atom or a sulfur atom, and Rrepresents substituted or unsubstituted lower alkyl and the like) and the like, Rrepresents substituted or unsubstituted lower alkyl and the like, and Rrepresents substituted or unsubstituted aryl and the like] and the like are provided.

Mitotic kinesin inhibitor

A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): [wherein, Rrepresents optionally substituted lower alkyl or the like; Rrepresents optionally substituted cycloalkyl or the like; Rrepresents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.

Imidazole derivatives

The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoic acid derivative represented by General Formula (I): [wherein n represents an integer of 0 to 10; Rrepresents substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted aroyl, or the like; Rrepresents &#x2014;NRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl or the like; and Rand Rmay be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl or the like] or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoic acid derivative or said prodrug.

Hsp90 family protein inhibitors

(wherein n is an integer of 0 to 10; Rrepresents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted heterocyclic-alkyl, substituted or unsubstituted aryl, &#x2014;CONRR, &#x2014;NRR, etc.; Rrepresents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; Rand Rmay be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, etc.; Rand Rmay be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, etc.) Provided are an Hsp90 family protein inhibitor comprising, as an active ingredient, a benzene derivative of formula (I) or a prodrug thereof or a pharmaceutically-acceptable salt thereof, etc.

Staurosporin derivatives

Growing community of inventors

Sakai, Japan

Yushi Kitamura